Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New AI-Powered Lung Imaging Solution Launched at RSNA 2018

By HospiMedica International staff writers
Posted on 26 Nov 2018
VIDA Diagnostics, Inc. More...
(Coralville, IA, USA), a pulmonary imaging analytics company, launched LungPrint Discovery, an artificial intelligence (AI)-powered lung analysis solution for radiologists, at the Radiological Society of North America's (RSNA) 104th Scientific Assembly and Annual Meeting, held November 25-30 in Chicago, Ill., USA.

VIDA is focused on transforming pulmonary care through intelligence. Powered by a combination of AI and quality-controlled image analysis services, VIDA's solution aims to provide greater precision and personalization across a range of lung diseases, including cancer, emphysema, airway obstructive diseases, asthma and interstitial lung disease. Like a fingerprint, each lung is unique. The LungPrint family of products, starting with LungPrint Discovery, aims to reveal each patient's unique lung profile in a manner that is clinically meaningful and efficient, helping VIDA deliver on its mission to transform lung care through information and intelligence.

LungPrint Discovery, a part of the VIDA|vision Software Suite, provides fully automatic quantification of lung physiology and function, including both tissue and airway analysis. LungPrint Discovery also features an airway visualization called "Hyperion View" with the potential to significantly accelerate airway reading and interpreting the complex airway anatomy.

"I've had the opportunity to preview VIDA's LungPrint Discovery and it is a game-changer for the reporting of thoracic CT scans," said Dr. John Newell, Professor of Radiology at the University of Iowa. "It will empower radiologists to provide a richer set of quantitative CT lung information with a state-of-the-art CT report for the referring physician. The new airway display is remarkable."

"We are pleased to serve radiologists with a product that delivers on the promises of AI, namely greater and proven clinical precision in tandem with efficiency gains," said Susan A. Wood, PhD, CEO of VIDA. "Our solution continually evolves and is designed with leading clinicians and clinically validated through large-scale trials. With seamless integration into the radiology workflow, our best-in-class solution can be used with a broadening audience and make a greater impact on pulmonary patient care."

Related Links:
VIDA Diagnostics


Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Cardiograph Device
PageWriter TC35
Newborn Hearing Screener
ALGO 7i
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.